Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Elk River Wealth Management LLC

Elk River Wealth Management LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 92.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,763 shares of the medical research company’s stock after selling 68,400 shares during the quarter. Elk River Wealth Management LLC’s holdings in Edwards Lifesciences were worth $427,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Abacus Planning Group Inc. lifted its holdings in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after buying an additional 140 shares in the last quarter. Private Advisor Group LLC lifted its holdings in Edwards Lifesciences by 79.4% in the 4th quarter. Private Advisor Group LLC now owns 21,326 shares of the medical research company’s stock worth $1,579,000 after buying an additional 9,440 shares in the last quarter. Pegasus Asset Management Inc. raised its stake in shares of Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 1,013.3% in the 4th quarter. Venturi Wealth Management LLC now owns 2,683 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 2,442 shares in the last quarter. Finally, D.A. Davidson & CO. raised its stake in shares of Edwards Lifesciences by 3.1% in the 4th quarter. D.A. Davidson & CO. now owns 10,033 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Truist Financial restated a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 1.2 %

Edwards Lifesciences stock opened at $74.73 on Thursday. The firm has a 50 day simple moving average of $72.84 and a 200-day simple moving average of $69.82. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $44.07 billion, a PE ratio of 10.72, a price-to-earnings-growth ratio of 4.92 and a beta of 1.10. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.